Cost of Alzheimer's Drug Could Push Medicare to the Brink

The Food and Drug Administration's approval of a new drug to treat Alzheimer's disease could have enormous implications not just for patients, but for Medicare—even pushing the program toward collapse. FDA approval historically has meant Medicare will cover the cost of the medication, but with Biogen's product, that's complicated, Vox reports. Experts say there isn't enough evidence that the drug, aducanumab, works. Three advisers to the FDA quit when their panel's advice to withhold approval was ignored.

https://www.newser.com/story/307256/cost-of-alzheimers-drug-could-push-medicare-to-the-brink.html
 


Back
Top